ProShare Advisors LLC decreased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,336 shares of the company’s stock after selling 296 shares during the period. ProShare Advisors LLC’s holdings in Omnicell were worth $1,868,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of OMCL. Neuberger Berman Group LLC purchased a new position in shares of Omnicell during the first quarter valued at about $119,344,000. Principal Financial Group Inc. lifted its holdings in shares of Omnicell by 39.8% in the 2nd quarter. Principal Financial Group Inc. now owns 426,356 shares of the company’s stock valued at $64,572,000 after acquiring an additional 121,470 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in shares of Omnicell by 28.5% in the 2nd quarter. Eagle Asset Management Inc. now owns 540,034 shares of the company’s stock valued at $81,788,000 after acquiring an additional 119,934 shares during the last quarter. Allianz Asset Management GmbH lifted its holdings in shares of Omnicell by 103.1% in the 1st quarter. Allianz Asset Management GmbH now owns 178,926 shares of the company’s stock valued at $23,237,000 after acquiring an additional 90,847 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Omnicell by 40.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 284,631 shares of the company’s stock valued at $36,965,000 after acquiring an additional 82,588 shares during the last quarter.
Omnicell stock opened at $159.69 on Thursday. The company has a 50 day moving average price of $155.65 and a 200-day moving average price of $146.70. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.78 and a current ratio of 3.10. Omnicell, Inc. has a fifty-two week low of $78.13 and a fifty-two week high of $163.78. The company has a market capitalization of $6.94 billion, a PE ratio of 122.84, a P/E/G ratio of 4.97 and a beta of 1.04.
In related news, CFO Peter J. Kuipers sold 11,500 shares of Omnicell stock in a transaction that occurred on Friday, August 6th. The shares were sold at an average price of $157.88, for a total transaction of $1,815,620.00. Following the transaction, the chief financial officer now directly owns 59,812 shares of the company’s stock, valued at $9,443,118.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Dan S. Johnston sold 31,236 shares of Omnicell stock in a transaction that occurred on Tuesday, July 20th. The shares were sold at an average price of $151.35, for a total transaction of $4,727,568.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 96,284 shares of company stock worth $14,728,766. 2.63% of the stock is currently owned by corporate insiders.
OMCL has been the subject of a number of analyst reports. TheStreet raised shares of Omnicell from a “c+” rating to a “b+” rating in a report on Thursday, July 29th. Zacks Investment Research downgraded shares of Omnicell from a “hold” rating to a “sell” rating and set a $162.00 price objective for the company. in a research note on Friday, July 9th. Piper Sandler raised their price objective on shares of Omnicell from $152.00 to $188.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 23rd. Finally, BTIG Research reissued a “buy” rating and issued a $151.49 price objective (down previously from $165.00) on shares of Omnicell in a research note on Tuesday, July 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and a consensus target price of $141.06.
Omnicell Company Profile
Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.
Read More: What is a growth and income fund?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.